The direct-acting antivirals for hepatitis C virus and the risk for hepatocellular carcinoma

Autores: Chinchilla López Paulina, Xingshun Qi, Yoshida Eric M, Méndez Sánchez Nahum

Resumen

The increase of incidences of Hepatocellular Carcinoma (HCC) will continue in the next decades. The therapies about hepatitis C infection has been questioned as a risk factor. Some authors emphasized that sustained virologic response (SVR) with interferon-based therapy reduced the risk of developing HCC. In contrast, some publications that to suggest an increasing risk of HCC in patients treated with Direct-Acting Antivirals (DAA). Whether these therapies are associated with an increased risk of HCC remains to be studied and continued long-term observational studies will be needed. The goal in HCV care needs to go beyond merely achieving an SVR.

Palabras clave: Liver cancer drugs hepatitis.

2017-05-03   |   297 visitas   |   Evalua este artículo 0 valoraciones

Vol. 16 Núm.3. Mayo-Junio 2017 Pags. 328-330 Ann Hepatol 2017; 16(3)